載入中
HKSEHealthcareMedical - Pharmaceuticals
最新資料
HK$4.38
+HK$0.04 · +0.92%
China Resources Pharmaceutical Group Limited, an investment holding company, engages in the manufacture, distribution, and retail of pharmaceutical and other healthcare products in Mainland China and internationally. It operates through four segments: Pharmaceutical Manufacturing, Pharmaceutical Distribution, Pharmaceutical Retail, and Others. The company offers a range of chemical drugs, Chinese medicines, and biological drugs, as well as nutritional and healthcare products for various therapeutic areas, including cardiovascular and cerebrovascular diseases, alimentary tract, endocrine diseases, respiratory diseases, orthopedics, nephrology, rheumatology and immunology, medical nutrition, pediatrics, genitourinary system, dermatological diseases, blood products, therapeutic infusions, antitumor drugs, medicine for cough and cold, anti-infection drugs, and psychoneurosis. It also provides warehousing, logistics, and other value-added pharmaceutical supply chain solutions and related services to pharmaceutical/medical device manufacturers and dispensers, such as hospitals, distributors, and retail pharmacies. In addition, the company is involved in property holding activities, as well as operates retail pharmacies under the Teck Soon Hong brands. It distributes its products under the 999, Dong-E-E-Jiao, Double Crane, Zizhu, Jiangzhong, Boya, and Kun Zhong Yao to hospitals and other medical institutions. The company was formerly known as China Resources Medications Group Limited and changed its name to China Resources Pharmaceutical Group Limited in December 2011. The company was incorporated in 2007 and is based in Wan Chai, Hong Kong. China Resources Pharmaceutical Group Limited is a subsidiary of CRH (Pharmaceutical) Limited.
最新資料
HK$4.38
+HK$0.04 · +0.92%
盤中時間採用HKT。市場資料可能有所延遲。
China Resources Pharmaceutical Group Limited, an investment holding company, engages in the manufacture, distribution, and retail of pharmaceutical and other healthcare products in Mainland China and internationally. It operates through four segments: Pharmaceutical Manufacturing, Pharmaceutical Distribution, Pharmaceutical Retail, and Others. The company offers a range of chemical drugs, Chinese medicines, and biological drugs, as well as nutritional and healthcare products for various therapeutic areas, including cardiovascular and cerebrovascular diseases, alimentary tract, endocrine diseases, respiratory diseases, orthopedics, nephrology, rheumatology and immunology, medical nutrition, pediatrics, genitourinary system, dermatological diseases, blood products, therapeutic infusions, antitumor drugs, medicine for cough and cold, anti-infection drugs, and psychoneurosis. It also provides warehousing, logistics, and other value-added pharmaceutical supply chain solutions and related services to pharmaceutical/medical device manufacturers and dispensers, such as hospitals, distributors, and retail pharmacies. In addition, the company is involved in property holding activities, as well as operates retail pharmacies under the Teck Soon Hong brands. It distributes its products under the 999, Dong-E-E-Jiao, Double Crane, Zizhu, Jiangzhong, Boya, and Kun Zhong Yao to hospitals and other medical institutions. The company was formerly known as China Resources Medications Group Limited and changed its name to China Resources Pharmaceutical Group Limited in December 2011. The company was incorporated in 2007 and is based in Wan Chai, Hong Kong. China Resources Pharmaceutical Group Limited is a subsidiary of CRH (Pharmaceutical) Limited.
日內區間
目前HK$4.38
52週區間
目前HK$4.38
盤中時間採用HKT。市場資料可能有所延遲。
China Resources Pharmaceutical Group Limited, an investment holding company, engages in the manufacture, distribution, and retail of pharmaceutical and other healthcare products in Mainland China and internationally. It operates through four segments: Pharmaceutical Manufacturing, Pharmaceutical Distribution, Pharmaceutical Retail, and Others. The company offers a range of chemical drugs, Chinese medicines, and biological drugs, as well as nutritional and healthcare products for various therapeutic areas, including cardiovascular and cerebrovascular diseases, alimentary tract, endocrine diseases, respiratory diseases, orthopedics, nephrology, rheumatology and immunology, medical nutrition, pediatrics, genitourinary system, dermatological diseases, blood products, therapeutic infusions, antitumor drugs, medicine for cough and cold, anti-infection drugs, and psychoneurosis. It also provides warehousing, logistics, and other value-added pharmaceutical supply chain solutions and related services to pharmaceutical/medical device manufacturers and dispensers, such as hospitals, distributors, and retail pharmacies. In addition, the company is involved in property holding activities, as well as operates retail pharmacies under the Teck Soon Hong brands. It distributes its products under the 999, Dong-E-E-Jiao, Double Crane, Zizhu, Jiangzhong, Boya, and Kun Zhong Yao to hospitals and other medical institutions. The company was formerly known as China Resources Medications Group Limited and changed its name to China Resources Pharmaceutical Group Limited in December 2011. The company was incorporated in 2007 and is based in Wan Chai, Hong Kong. China Resources Pharmaceutical Group Limited is a subsidiary of CRH (Pharmaceutical) Limited.
日內區間
目前HK$4.38
52週區間
目前HK$4.38
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（HKD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 3000.13億 HKD | 2741.82億 HKD | 2703.97億 HKD | 2231.3億 HKD | 1932.36億 HKD |
| 銷貨成本 | 2504.8億 HKD | 2308.87億 HKD | 2284.07億 HKD | 1887.66億 HKD | 1643.66億 HKD |
| 毛利 | 495.33億 HKD | 432.96億 HKD | 424.32億 HKD | 343.64億 HKD | 288.71億 HKD |
| 研究與開發 | 31.54億 HKD | 24.75億 HKD | 27.29億 HKD | 18.35億 HKD | 13.78億 HKD |
| 銷售、一般及管理費用 | 324.77億 HKD | 282.59億 HKD | 277.91億 HKD | 192.95億 HKD | 158.53億 HKD |
| 營業費用 | 356.31億 HKD | 307.32億 HKD | 305.2億 HKD | 248.7億 HKD | 213.24億 HKD |
| 利息收入 | 5.25億 HKD | 6.81億 HKD | 5.88億 HKD | 7.32億 HKD | 5.95億 HKD |
| 利息支出 | 21.98億 HKD | 22.82億 HKD | 23.86億 HKD | 25.06億 HKD | 22.12億 HKD |
| 折舊和攤銷 | 44.66億 HKD | 36.07億 HKD | 34.22億 HKD | 27.68億 HKD | 23.48億 HKD |
| 營業利益 | 139.02億 HKD | 125.62億 HKD | 139.01億 HKD | 94.94億 HKD | 75.47億 HKD |
| 淨利 | 45.02億 HKD | 35.66億 HKD | 42.4億 HKD | 36.42億 HKD | 30.75億 HKD |
公司資料更新於 2026年10月10日。
近期已公布業績
近期已公布業績
報告持有此股票曝險的交易所交易基金。
Vanguard FTSE Emerging Markets ETFVWO1521.46萬0.01%1685億 USD0.06%US$59.76+1.12%
Vanguard Total International Stock ETFVXUS1511.29萬0.00%6657億 USD0.05%US$84.82+0.86%
iShares Core MSCI Emerging Markets ETFIEMG1114.45萬0.01%1589.63億 USD0.09%US$81.40+1.12%
JPMorgan International Value ETFJIVE615.6萬0.15%42.21億 USD0.55%US$94.4295+0.50%
First Trust Emerging Markets AlphaDEX FundFEM238.36萬0.29%8.15億 USD0.80%US$33.1628+1.35%
Vanguard FTSE All-World ex-US ETFVEU237.2萬0.00%986億 USD0.04%US$82.82+0.78%
Avantis Emerging Markets Equity ETFAVEM209.18萬0.01%281.73億 USD0.33%US$94.11+0.93%
Vident International Equity Strategy ETFVIDI195.39萬0.44%4.42億 USD0.61%US$39.73+1.07%Vanguard FTSE Emerging Markets ETFVWOVanguard Total International Stock ETFVXUSiShares Core MSCI Emerging Markets ETFIEMGJPMorgan International Value ETFJIVEFirst Trust Emerging Markets AlphaDEX FundFEMVanguard FTSE All-World ex-US ETFVEUAvantis Emerging Markets Equity ETFAVEMVident International Equity Strategy ETFVIDIAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
